Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 1998

Primary Completion Date

December 31, 2005

Study Completion Date

February 28, 2006

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
BIOLOGICAL

anti-thymocyte globulin

The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).

DRUG

busulfan

The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).

DRUG

cyclophosphamide

The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).

DRUG

melphalan

The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).

DRUG

methylprednisolone

The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).

PROCEDURE

bone marrow ablation with stem cell support

PROCEDURE

umbilical cord blood transplantation

One day after the conditioning regimen is completed, patients receive the UCBT.

RADIATION

radiation therapy

The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).

Trial Locations (1)

44106-7284

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00003336 - Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions | Biotech Hunter | Biotech Hunter